For the primary MM tumor treatment (n=6 for each combination), the MAPK inhibitor GSK1120212, FAK inhibitor TAE226 and PI3K inhibitor BKM120 were chosen based on the data generated from HMCL. The gene discussed is PTK2; the disease is Miyoshi myopathy.